Coronavirus News Roundup: Pfizer Announces 90% Efficacy Rate for Vaccine, FDA Grants EUA to Bamlanivimab

November 13, 2020

Here’s a roundup of the latest coronavirus-related news.

The number of coronavirus disease 2019 (COVID-19) cases in the United States are rapidly increasing, with hospitalization rates setting a national record on Thursday for the third day in a row, according to The COVID Tracking Project. This week, Pfizer announced a 90% efficacy rate for its investigational COVID-19 vaccine based in early data, and the FDA granted emergency use authorization (EUA) for bamlanivimab to treat mild-to-moderate COVID-19 infection.

Here’s a roundup of the latest coronavirus-related news:

AmerisourceBergen Reaches Agreement with CDC to Support Independent Retail Pharmacies’ Access to COVID-19 Vaccine

AmerisourceBergen has reached an agreement with the CDC to include Good Neighbor Pharmacy and Elevate Provider Network members in the Federal Pharmacy Partnership Strategy for COVID-19 Vaccination.

Read more

FDA Fast Tracks Novavax’s COVID-19 Vaccine Candidate

The FDA has granted Fast Track Designation for Novavax’s vaccine candidate for COVID-19.

Read more

FDA Grants EUA to Bamlanivimab for COVID-19

The FDA granted EUA to bamlanivimab (LY-CoV555), Eli Lilly’s investigational neutralizing antibody for the treatment of mild-to-moderate COVID-19.

Read more

Pfizer’s COVID-19 Vaccine Shows 90% Efficacy Rate in Interim Analysis

Pfizer and BioNTech’s investigational vaccine candidate for COVID-19 was found to be more than 90% effective, according to results of an interim analysis.

Read more

NORD Report: COVID-19 Telehealth Surge Especially Important for People With Rare Diseases

Millions of Americans need continued access to telehealth services, especially those with rare disorders, many of which are autoimmune diseases, according to the National Organization for Rare Disorders (NORD).

Read more on Managed Healthcare Executive

Related Content:

Coronavirus